Previous 10 | Next 10 |
2024-03-05 13:27:40 ET Summary Avidity Biosciences stock has gained more than 20% in the past five days due to positive long-term data for its lead candidate, AOC 1001, in the MARINA-OLE trial in DM1 patients. The company's market cap valuation is approximately $1.5 billion. Its I...
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial PR Newswire Avidity accelerates global P...
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement PR Newswire Funding from new and existing investors, including Adage Capital Partners LP, Boxer Capital, Casdin Capital, LLC, Farallon, Janus Henderson Investors, RA Capital Management, RTW Investments...
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights PR Newswire Avidity is on-track to initiate global Phase 3 HARBOR ™ trial of AOC 1001 for DM1 in mid-2024 Company to share first-look at long-term efficacy a...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping PR Newswire SAN DIEGO , Feb. 20, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RN...
Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Avidity Biosciences to Present New AOC 100...
2024-01-26 14:42:19 ET More on Dyne Therapeutics Assessing Dyne Therapeutics' Muscular Dystrophy Data: Early Promise, Caution Needed Dyne Therapeutics prices stock offering to raise $300.1 million Biggest stock movers today: Crypto stocks, SoFi Technologies, Bloomin'...
2024-01-11 03:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth PR Newswire Avidity plans to initiate global Phase 3 HARBOR ™ trial of AOC 1001 for DM1 mid-2024 Company to report data from all three ongoing clinical program...
News, Short Squeeze, Breakout and More Instantly...
Avidity Biosciences Inc. Company Name:
RNA Stock Symbol:
NASDAQ Market:
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights PR Newswire Initiation of global Phase 3 HARBOR ™ trial for d el-desiran (AOC 1001) in DM1 on track for this quarter Avidity to report FSHD data from FORTI...
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1 PR Newswire Avidity initiating global Phase 3 HARBOR™ study for delpacibart etedesiran this quarter Delpa...
2024-04-04 11:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...